Clinical Trial Update: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating whether adding bortezomib to combination chemotherapy improves outcomes in younger patients with newly diagnosed T-cell acute lymphob…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoblastic Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-02-23